Albany – NY, Oct. 20, 2015 (GLOBE NEWSWIRE) — A new report published by Transparency Market Research on the global glioblastoma treatment market provides insights into the growth drivers, potential restraints, and growth opportunities that the market is likely to witness between 2014 and 2022. The report is titled “Glioblastoma Multiforme Treatment (GBM) Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 – 2022” and is available for sale in the company website. The market, according to the report, will grow from a valuation of US 0.34 bn in 2013 to US$0.91 bn in 2022, exhibiting a positive CAGR of 11.40% during the period.
Browse the full Pipeline Review of Glioblastoma Treatment Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 – 2022 report at http://www.transparencymarketresearch.com/pipeline-review-of-glioblastoma-treatment-market.html
Glioblastoma multiforme (GBM) is the most lethal and common brain tumor in adults. The treatment modalities available in the market at present include surgical resection, followed by radiotherapy and chemotherapy. Despite being around in the healthcare industry since the last few years, these modalities have done little to decrease the overall mortality rate in patients. Recurrence of disease, glioma stem cell resistance to conventional modalities, and invasiveness of GBM are a few factors hampering the success rate of available treatment methods.
Novel treatment strategies are, therefore, desperately required to address such unmet medical needs, and the GBM pipeline already includes a mix of small molecules, immunotherapy, biological, and other types of therapeutics. Advances introduced in gene technology and molecular biology also provide lucrative novel possibilities for efficient treatment of patients diagnosed with GBM. The report discusses the aforementioned factors in detail as the most crucial growth drivers of the glioblastoma treatment market.
Some of the glioblastoma treatments approved by the FDA include bevacozumab, temozolomide, and carmustine. Of these, carmustine, known by the brand name Gliadel (a product of Arbor Pharmaceuticals, LLC), is surgical implant. Likewise, bevacozumab, brand named Avastin by Genetech/Roche, is used for intravenous therapy and temozolomide (brand named Temodal/Temodar/Temcad) is primarily recommended for oral or intravenous chemotherapy. The report analyzes the market dynamics of these available drugs and therapies. It also studies their effectiveness in glioblastoma treatment to measure the scope for novel therapies.
According to the report, rising awareness regarding the types of brain tumors, increased funding for R&D in drug delivery technologies, and the introduction of modern diagnostic techniques fuel the market for glioblastoma treatment. Among the available modalities, in 2013, the glioblastoma treatment market was dominated by temozolomide. However, the drug recently lost its patent, allowing generic drugs to foray into the market and significantly bring down the market share of temozolomide.
Among the regional markets for glioblastoma treatment, North America occupied the leading position due to the high incidence of glioblastoma multiforme in the region. The presence of an increasing number of associations, such as the National Brain Tumor Society, the American Brain Tumor Association, the Brain Tumor Foundation of Canada, and others, that are engaged in boosting the awareness regarding GBM across the region is aiding the growth of the North America glioblastoma treatment market.
Moreover, most prominent GBM drug manufacturers are located in the region, which further fuels the glioblastoma treatment market in North America. Asia Pacific, according to the report, will emerge as the most lucrative market for glioblastoma treatment drugs in the coming years. Rising awareness regarding GBM and rapid development of the healthcare infrastructure in several countries in Asia Pacific is propelling the glioblastoma treatment market in the region.
The pipeline review of glioblastoma treatment market has been segmented as below:
- Global Glioblastoma Treatment Market Revenue and Forecast, by Drugs
- Bevacizumab (Avastin)
- Temozolomide (Temodar and Temodal and Temcad)
- Carmustine (BiCNU)
- Global Glioblastoma Treatment Market Revenue and Forecast, by Geography
- North America
- Asia Pacific
- Rest of the World
- Global Pipeline Review of Glioblastoma Treatment
- Late Stage (Phase III)
- Rindopepimut (CDX-110)
- Early Stage (Phase I, II and Pre clinical)
Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather, and analyze information.
Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.
CONTACT: Mr. Nachiket Ghumare 90 State Street, Suite 700 Albany, NY 12207 Tel: +1-518-618-1030 USA - Canada Toll Free: 866-552-3453 Email: email@example.com Website: http://www.transparencymarketresearch.com